Anatomical and Functional Outcomes of Vitrectomy with/without Intravitreal Methotrexate Infusion for Management of Proliferative Vitreoretinopathy Secondary to Rhegmatogenous Retinal Detachment

Table 5

Effect of number of recurrences on anatomical outcome and mean visual acuity in each subgroup and control.

Anatomical outcome						value
				Successful	Recurrent
Subgroups based on MTX indication	Control 1	Number of recurrences	0	3	0	0.4
			1	9	1
			2	8	3
			3	3	0
			4	3	0
	Established PVR	Number of recurrences	0	9	4	0.7
			1	14	3
			2	5	2
			3	2	2
			4	1	0
	Control 2	Number of recurrences	0	28	2	—
	High-risk PVR	Number of recurrences	0	26	7	0.4
			1	1	1
	Control 3	Number of recurrences	0	23	6	—
	No risk of PVR	Number of recurrences	0	23	1	—

MTX, methotrexate; PVR, proliferative vitreoretinopathy. is significant at <0.05.